BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY : Impact Factor & More
eISSN: 1179-9889pISSN: 1179-9889
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY Journal Specifications
Indexed in the following public directories
Web of Science 
DOAJ
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2011 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY
Metabolic Subtypes Predict Treatment Response in Acute Myeloid Leukemia: A Pilot Study.
- 1 Jun 2026
- Blood and lymphatic cancer : targets and therapy
A Risk Model Using Refined Disease Risk Index and 1-Month NK-Cell Count for Relapse in Children and Adults with T-ALL/LBL After Myeloablative Umbilical Cord Blood Transplantation
- 22 May 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia
- 19 May 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study.
- 1 Apr 2026
- Blood and lymphatic cancer : targets and therapy
Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect.
- 1 Apr 2026
- Blood and lymphatic cancer : targets and therapy
Prognostic Value of the Aggregate Inflammation Systemic Index (AISI) in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study
- 31 Mar 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Metabolic Subtypes Predict Treatment Response in Acute Myeloid Leukemia: A Pilot Study.
- 1 Jun 2026
- Blood and lymphatic cancer : targets and therapy
A Risk Model Using Refined Disease Risk Index and 1-Month NK-Cell Count for Relapse in Children and Adults with T-ALL/LBL After Myeloablative Umbilical Cord Blood Transplantation
- 22 May 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia
- 19 May 2026
- Blood and Lymphatic Cancer: Targets and Therapy
Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study.
- 1 Apr 2026
- Blood and lymphatic cancer : targets and therapy
Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect.
- 1 Apr 2026
- Blood and lymphatic cancer : targets and therapy
Prognostic Value of the Aggregate Inflammation Systemic Index (AISI) in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study
- 31 Mar 2026
- Blood and Lymphatic Cancer: Targets and Therapy
FAQs on BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY
How long has BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY been actively publishing? 
What is the publishing frequency of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY?
How many articles did BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY publish last year?
What is the eISSN & pISSN for BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY?
Who is the publisher of BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY?
